HDBuzz has been following SKY-0515 since the first results from its Phase 1 study were announced in 2024. Early testing in ...

12 min read | Unique research highlights an overlooked mental health disparity among Indigenous North American people with HD – and the need for care grounded in trust, community partnership, and ...

First to speak was Aikaterini Papadopoulou, who talked about her work targeting a fragment of the expanded HTTHTT one abbreviation for the gene that causes Huntington’s disease. The same gene is also ...

A new collaboration between researchers at Indiana University Southeast and Bellarmine University in Kentucky, both in the USA, aimed to investigate what happens when a physical therapist and a music ...

⏱️10 min read | Results from the VIBRANT-HD trial are now published in a peer reviewed journal. This trial tested the oral drug, branaplam, which lowered HTT but had serious safety problems, ...

Long-time HDBuzz readers may recognise pridopidine. Pridopidine has had one of the longest and most winding development journeys of any experimental HD therapy. Originally developed as a treatment for ...

Skyhawk Therapeuticstherapeutics treatments has announced results from a Phase 1 clinical study of its experimental huntingtin-lowering drug, SKY-0515. As with all Phase 1 studies, the main goal was ...

In plain language. Written by scientists. A gene called MSH3 helps to repair our DNA, but in HD it can slip up and cause CAG repeats to lengthen. Researchers have uncovered new information about how ...

In plain language. Written by scientists. We're proud to announce Molly Gracey as a 2024 HDBuzz Prize winner! Could social skills be the secret ingredient to a better quality of life in people with ...

In plain language. Written by scientists. ⏱️8 min read | What if nutrition is one of the warning lights we should be checking earlier in Huntington’s disease? New research suggests simple nutrition ...

In plain language. Written by scientists. Skyhawk shared data at the 15 month mark for SKY-0515 treatment in people with HD in their Phase 1/2 trial. The drug is working as designed and there are some ...